HRP20161612T2 - Sulfatne soli n-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amina, njihova priprava i uporaba istih - Google Patents

Sulfatne soli n-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amina, njihova priprava i uporaba istih Download PDF

Info

Publication number
HRP20161612T2
HRP20161612T2 HRP20161612TT HRP20161612T HRP20161612T2 HR P20161612 T2 HRP20161612 T2 HR P20161612T2 HR P20161612T T HRP20161612T T HR P20161612TT HR P20161612 T HRP20161612 T HR P20161612T HR P20161612 T2 HRP20161612 T2 HR P20161612T2
Authority
HR
Croatia
Prior art keywords
disease
sulfate salt
pharmaceutically acceptable
propyl
salt according
Prior art date
Application number
HRP20161612TT
Other languages
English (en)
Croatian (hr)
Inventor
Stéphane BURLET
Cécilia ESTRELLA
Mathieu BARRIER
Patricia Melnyk
Nicolas Sergeant
Luc Buee
Philippe Verwaerde
Original Assignee
Alzprotect
Inserm
Université De Lille 2 Droit Et Santé
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alzprotect, Inserm, Université De Lille 2 Droit Et Santé filed Critical Alzprotect
Publication of HRP20161612T1 publication Critical patent/HRP20161612T1/hr
Publication of HRP20161612T2 publication Critical patent/HRP20161612T2/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20161612TT 2012-12-27 2013-12-27 Sulfatne soli n-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amina, njihova priprava i uporaba istih HRP20161612T2 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306690 2012-12-27
EP13815780.5A EP2938597B1 (en) 2012-12-27 2013-12-27 Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same
PCT/EP2013/078068 WO2014102339A1 (en) 2012-12-27 2013-12-27 Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same

Publications (2)

Publication Number Publication Date
HRP20161612T1 HRP20161612T1 (hr) 2017-01-27
HRP20161612T2 true HRP20161612T2 (hr) 2017-02-24

Family

ID=47501005

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161612TT HRP20161612T2 (hr) 2012-12-27 2013-12-27 Sulfatne soli n-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amina, njihova priprava i uporaba istih

Country Status (23)

Country Link
US (3) US9562018B2 (https=)
EP (1) EP2938597B1 (https=)
JP (1) JP6384923B2 (https=)
KR (1) KR102115060B1 (https=)
CN (1) CN105008333B (https=)
AU (2) AU2013369288B2 (https=)
BR (1) BR112015015474B1 (https=)
CA (1) CA2895285C (https=)
DK (1) DK2938597T3 (https=)
ES (1) ES2605494T3 (https=)
HR (1) HRP20161612T2 (https=)
HU (1) HUE030930T2 (https=)
IL (1) IL239450B (https=)
LT (1) LT2938597T (https=)
MX (1) MX363367B (https=)
NZ (1) NZ708959A (https=)
PL (1) PL2938597T3 (https=)
PT (1) PT2938597T (https=)
RS (1) RS55511B1 (https=)
RU (1) RU2655454C2 (https=)
SI (1) SI2938597T1 (https=)
WO (1) WO2014102339A1 (https=)
ZA (1) ZA201504521B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2938597T1 (sl) 2012-12-27 2017-03-31 Alzprotect Sulfatne soli n-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h- benzo(d)imidazol-2-amin, njihova priprava in uporaba istega
WO2016146655A1 (en) 2015-03-16 2016-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel 1,4-bis(3-aminopropyl)piperazine derivative and its use
TWI744300B (zh) * 2016-03-23 2021-11-01 里爾中央醫學中心 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途
AU2021353998B2 (en) * 2020-10-01 2024-02-29 Alzprotect Succinate salts of N-(3-(4-(3-(Diisobutylamino)Propyl)Piperazin-1-YL)Propyl)-1H-Benzo[D]Imidazol-2-Amine, Preparation Thereof And Use Of The Same
WO2022074093A1 (en) * 2020-10-07 2022-04-14 Alzprotect Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine sulphate salts and solvates thereof for the treatment of motor neuron diseases and neuromuscular junction disorders
CA3243012A1 (en) 2021-12-20 2023-06-29 Alzprotect USE OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[D]IMIDAZOL-2-AMINE SUCCINATE SALTS AND ASSOCIATED SOLVATES FOR THE TREATMENT OF MOTOR NERVE DISEASES AND NEUROMUSCULAR JUNCTION DISORDERS
US20250205226A1 (en) 2022-03-25 2025-06-26 Alzprotect Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine salts and solvates thereof for the treatment of sensory neuron diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2674856B1 (fr) * 1991-04-05 1993-07-30 Esteve Labor Dr Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments.
CA2263367A1 (fr) * 1997-06-12 1998-12-17 Transgene S.A. Nouveaux complexes lipidiques pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
AU6280199A (en) 1998-09-30 2000-04-17 Neurogen Corporation 2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands
WO2002096431A1 (en) * 2001-05-25 2002-12-05 The Regents Of The University Of California Optically active compounds clearing malformed proteins
US20040116441A1 (en) * 2002-10-30 2004-06-17 Pfizer Inc Methods of using sulfonic acid derivatives
JP4660199B2 (ja) * 2002-12-23 2011-03-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換1−ピペリジン−4−イル−4−アゼチジン−3−イル−ピペラジン誘導体およびそれらのニューロキニン拮抗薬としての使用
CA2585983C (en) * 2004-11-10 2014-03-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases
SI2938597T1 (sl) * 2012-12-27 2017-03-31 Alzprotect Sulfatne soli n-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h- benzo(d)imidazol-2-amin, njihova priprava in uporaba istega

Also Published As

Publication number Publication date
US20160108003A1 (en) 2016-04-21
ES2605494T3 (es) 2017-03-14
US20170151235A1 (en) 2017-06-01
EP2938597A1 (en) 2015-11-04
JP6384923B2 (ja) 2018-09-05
KR20150105313A (ko) 2015-09-16
NZ708959A (en) 2019-11-29
CA2895285C (en) 2021-03-30
IL239450A0 (en) 2015-07-30
AU2013369288A1 (en) 2015-07-02
BR112015015474B1 (pt) 2022-04-19
HUE030930T2 (hu) 2017-06-28
JP2016503813A (ja) 2016-02-08
LT2938597T (lt) 2017-01-25
RU2015130671A (ru) 2017-01-30
KR102115060B1 (ko) 2020-05-25
US20190381036A1 (en) 2019-12-19
AU2013369288B2 (en) 2018-02-22
PL2938597T3 (pl) 2017-03-31
SI2938597T1 (sl) 2017-03-31
CN105008333B (zh) 2018-02-09
DK2938597T3 (en) 2017-01-09
BR112015015474A2 (https=) 2017-08-15
CN105008333A (zh) 2015-10-28
HK1215582A1 (en) 2016-09-02
AU2018202218A1 (en) 2018-04-26
CA2895285A1 (en) 2014-07-03
RU2655454C2 (ru) 2018-05-29
HRP20161612T1 (hr) 2017-01-27
US10772884B2 (en) 2020-09-15
WO2014102339A1 (en) 2014-07-03
AU2018202218B2 (en) 2019-02-21
MX363367B (es) 2019-03-20
PT2938597T (pt) 2016-12-09
AU2013369288A8 (en) 2015-07-16
EP2938597B1 (en) 2016-10-26
MX2015008502A (es) 2015-12-16
ZA201504521B (en) 2016-11-30
RS55511B1 (sr) 2017-05-31
US10537569B2 (en) 2020-01-21
US9562018B2 (en) 2017-02-07
IL239450B (en) 2018-06-28

Similar Documents

Publication Publication Date Title
HRP20161612T2 (hr) Sulfatne soli n-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amina, njihova priprava i uporaba istih
HRP20241145T1 (hr) Biciklički aza spojevi kao agonisti muskarinskih receptora
HRP20211331T1 (hr) Inhibitor površinskog antigena hepatitis b virusa
HRP20140011T1 (hr) Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja
HRP20241020T1 (hr) Makrociklički spoj koji služi kao wee1 inhibitor i njegove primjene
HRP20201985T1 (hr) Piridonski spoj kao c-met inhibitor
EP2151435A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
HRP20211863T1 (hr) Formulacija za kontinuirano otpuštanje kolhicina i postupci priprave istog
EP2906974A4 (en) DIRECTLY WRITTEN LITHOGRAPHY FOR THE MANUFACTURE OF GEOMETRIC PHASE HOLOGRAMS
PH12017502351A1 (en) 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
EP2911664A4 (en) COMBINATION THERAPIES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES
PL2892563T3 (pl) Kompozycje farmaceutyczne do leczenia choroby alzheimera
HRP20211429T1 (hr) Derivati sobetiroma
EA200901373A1 (ru) Аминогетероциклические соединения
MX2015015893A (es) 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen.
JP2018168191A5 (https=)
HRP20171977T1 (hr) Derivati dolastatina 10 i auristatina
HRP20130007T1 (hr) Lijeäśenje kognitivnih poremeä†aja pomoä†u (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamida i njegovih farmaceutski prihvatljivih soli
HRP20170025T1 (hr) Derivati tetrahidropirolotiazina kao inhibitori bace
IL288894A (en) Methods for the assessment and treatment of Alzheimer's disease and their applications
JP2012532125A5 (https=)
EP3861352A4 (en) NOVEL BIOMARKER FOR HUMAN ALZHEIMER'S DISEASE
JP2017537937A5 (https=)
HRP20200369T1 (hr) Halogenirani kvinazolin-thf-amini kao inhibitori pde1
JP2013531073A5 (https=)